NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Propanc Biopharma, Inc. (PPCB) Stock Analysis

Propanc Biopharma, Inc. (PPCB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PPCB

$1.01

−$0.01 (−0.98%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PPCB with… →

PPCB Key Statistics

As of Sep 4, 2026
Trading
Open
$1.05
Previous Close
$1.02
Day's Range
0.97–1.05
52-Week Range
0.95–65.00
Volume
178.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.33
Valuation
Market Cap
$2.30M
P/E Ratio
0.00
EPS (ttm)Profit attributable to each share over the last twelve months.
570.50
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$58.92M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.28M
1-Year Return
−48.99%
Dividend and dates
Avg Volume
5.51M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PPCB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+88.22%
2025+89333.33%

As of September 4, 2026.

PPCB Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$58.92M—
2024$0.00−$1.82M—
2023$0.00−$2.66M—
2022$0.00−$2.66M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$57.28M−$58.92M—
2024$0.00—−$1.54M−$1.82M—
2023$0.00—−$1.78M−$2.66M—
2022$0.00—−$1.99M−$2.66M—

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

PPCB Valuation vs Biotechnology Median

Median of 656 stocks
MetricPPCBBiotechnology medianvs median
P/E0.0012.570.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Propanc Biopharma, Inc. (PPCB) is capitalised at $2.30M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 1 employees.

Over the past 52 weeks the price has ranged from $0.95 to $65.00. PPCB last closed at $1.01 on September 4, 2026. That is −$0.01 (−0.98%) against the previous close. The latest close sits 6.32% above that 52-week low.

Financial Health

In fiscal 2025, Propanc Biopharma, Inc. reported revenue of $0.00. The same year closed with a net loss of $58.92M. The reported profit margin is 0%. Earnings per share on a trailing basis come to 570.5.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

PPCB trades at a trailing price-to-earnings ratio of 0.

The reported beta is 3.33. Daily returns over the trailing 1 year annualize to a volatility of 2,234.02%. The trailing one-year price return is −48.99%. The stored price history starts on January 13, 2025, and the total return since then is +168,233.33%.

Growth & Income

No dividend is on file for PPCB.

The record holds one complete calendar year, 2025, which returned +89,333.33%. 2026 is still running; the price is +88.22% year to date.

Peer Comparison

Propanc Biopharma, Inc. (PPCB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Propanc Biopharma, Inc. PPCB $2.30M 0.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Propanc Biopharma, Inc. trades at a P/E of 0.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Visit website →